Wellington Management Group LLP Cuts Position in Merck & Co., Inc. $MRK

Wellington Management Group LLP reduced its position in shares of Merck & Co., Inc. (NYSE:MRK) by 2.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 75,279,104 shares of the company’s stock after selling 1,577,388 shares during the period. Merck & Co., Inc. comprises about 1.1% of Wellington Management Group LLP’s holdings, making the stock its 11th largest holding. Wellington Management Group LLP owned about 3.03% of Merck & Co., Inc. worth $6,318,175,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Brighton Jones LLC grew its position in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC lifted its position in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock worth $910,000 after purchasing an additional 3,941 shares in the last quarter. Good Life Advisors LLC lifted its position in shares of Merck & Co., Inc. by 35.9% during the second quarter. Good Life Advisors LLC now owns 15,663 shares of the company’s stock worth $1,240,000 after purchasing an additional 4,141 shares in the last quarter. Oak Harvest Investment Services boosted its stake in shares of Merck & Co., Inc. by 7.7% in the second quarter. Oak Harvest Investment Services now owns 58,922 shares of the company’s stock valued at $4,664,000 after purchasing an additional 4,194 shares during the period. Finally, Donoghue Forlines LLC grew its holdings in shares of Merck & Co., Inc. by 17.7% in the second quarter. Donoghue Forlines LLC now owns 18,341 shares of the company’s stock valued at $1,452,000 after purchasing an additional 2,755 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $115.61 on Friday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $125.14. The firm’s fifty day simple moving average is $115.26 and its 200-day simple moving average is $99.58. The firm has a market capitalization of $285.84 billion, a price-to-earnings ratio of 15.88, a PEG ratio of 2.24 and a beta of 0.27. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $2.01 by $0.03. The firm had revenue of $16.40 billion during the quarter, compared to the consensus estimate of $16.19 billion. Merck & Co., Inc. had a net margin of 28.08% and a return on equity of 44.57%. The company’s revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.72 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. Equities analysts forecast that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, March 16th. Merck & Co., Inc.’s dividend payout ratio is currently 46.70%.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Unusually large call buying: traders bought ~672,962 call options on Friday (a ~1,339% jump vs. typical daily call volume), signaling heavy bullish speculation or hedging interest that can lift near-term implied volatility and upside pressure on MRK shares.
• Positive Sentiment: Phase 3 WELIREG data and regulatory filings deepen Merck’s oncology growth story — new Phase 3 results for belzutifan (WELIREG) combos with KEYTRUDA or LENVIMA show meaningful improvement in RCC; FDA filings with priority reviews/PDUFA dates for 2026 could expand label and revenue runway. Merck’s WELIREG Kidney Cancer Trials Deepen Oncology Growth Story
• Positive Sentiment: Analyst upgrades/price-target raises: Wells Fargo raised its price target to $150 and assigned an overweight rating, and Leerink lifted its target as well — both moves increase institutional demand signals and implied upside for MRK. Benzinga Leerink Raises Merck & Co. Inc. (MRK) Price Target
• Positive Sentiment: RBC Capital maintains a Buy rating, reinforcing analyst support and potentially bolstering demand from long-only managers. RBC Capital Sticks to Its Buy Rating for Merck & Company (MRK)
• Positive Sentiment: Bullish price commentary: coverage and price-target pieces (e.g., 247WallStreet) argue broader upside (some scenarios to $150) based on drug pipeline potential, supporting a favorable narrative among momentum investors. Merck Price Prediction: Sac-TMT Drug Potential Pushes MRK to $150
• Neutral Sentiment: Market report on Ovidrel/Ovitrelle highlights expanding fertility market opportunities that could be a modest long-term tailwind for related Merck products, but it’s not an immediate revenue catalyst. Ovidrel or Ovitrelle Market Research Report 2026
• Neutral Sentiment: Misc. coverage items (e.g., stock-picking lists and unrelated biotech moves) mention MRK in broader contexts but are unlikely to materially move the stock on their own. 1 Unpopular Stock That Deserves Some Love and 2 We Avoid ImmunityBio Stock Soars 295% YTD

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating and set a $150.00 target price on the stock in a research note on Friday, February 13th. Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research report on Saturday, February 28th. Barclays initiated coverage on Merck & Co., Inc. in a research note on Friday, February 20th. They issued an “overweight” rating and a $140.00 price objective on the stock. TD Cowen boosted their target price on Merck & Co., Inc. from $100.00 to $120.00 and gave the stock a “hold” rating in a research note on Tuesday, January 20th. Finally, The Goldman Sachs Group upped their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the stock a “buy” rating in a report on Tuesday, December 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $126.81.

Insider Buying and Selling at Merck & Co., Inc.

In related news, CFO Caroline Litchfield sold 41,997 shares of the company’s stock in a transaction that occurred on Wednesday, February 4th. The stock was sold at an average price of $119.61, for a total value of $5,023,261.17. Following the completion of the transaction, the chief financial officer directly owned 90,192 shares of the company’s stock, valued at $10,787,865.12. This represents a 31.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 37,685 shares of the stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $120.92, for a total transaction of $4,556,870.20. Following the completion of the transaction, the executive vice president owned 160,174 shares in the company, valued at $19,368,240.08. This represents a 19.05% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 320,176 shares of company stock worth $38,281,735. Corporate insiders own 0.13% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.